AIV Logo AIV Assistant

Loading...

 Logo Altimmune, Inc. - ALT Open Altimmune, Inc. in new tab

4.07
EPS
-1.18
P/B
2.08
ROE
-0.56
Beta
0.06

4.0700

4.070

Daily: +1.75%
Key Metrics

Earnings date: Nov. 11, 2025

EPS: -1.18

Book Value: 1.90

Price to Book: 2.08

Debt/Equity: 9.82

% Insiders: 0.008%

Growth

Revenue Growth: -0.17%

Estimates

Forward P/E: -2.69

Forward EPS: -1.47

 Logo About Altimmune, Inc. - (ALT)

Country: United States

Sector: Health Care

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Dividends

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion